Technetium Tc 99m trofolastat

Drug Profile

Technetium Tc 99m trofolastat

Alternative Names: 1404; 99mTc-MIP1404; 99mTc-trofolastat; F-1311; MIP-1404; MP-1404

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer FUJIFILM RI Pharma; Molecular Insight Pharmaceuticals
  • Class Antineoplastics; Imaging agents; Imidazoles; Organotechnetium compounds; Radiopharmaceuticals; Small molecules; Technetium compounds
  • Mechanism of Action Diagnostic imaging enhancers; Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 09 Mar 2017 Progenics has patent protection for technetium Tc 99m trofolastat in USA and countries outside USA
  • 09 Mar 2017 Progenics has patents pending for technetium Tc 99m trofolastat worldwide
  • 01 Apr 2016 FUJIFILM initiates enrolment in a phase IIb trial for Prostate cancer (Diagnosis) in Japan (JapicCTI163190)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top